Randomized, single-dose, open-label, two-part, two-period, cross-over study to compare the pharmacokinetics, safety and tolerability of the pediatric and adult formulation of branaplam and to investigate the adult formulation in fed and fasted state in healthy participants
Latest Information Update: 24 Oct 2022
At a glance
- Drugs Branaplam (Primary)
- Indications Huntington's disease
- Focus Pharmacokinetics
- Acronyms QSC205070
- Sponsors Novartis
Most Recent Events
- 06 Oct 2022 Status changed from recruiting to completed.
- 05 Sep 2022 Status changed from not yet recruiting to recruiting.
- 13 Apr 2022 New trial record